Once-Weekly Somatrogon in Pediatric Growth Hormone Deficiency: Real-World Efficacy, Safety, and Quality-of-Life Findings - PubMed
3 hours ago
- #pediatric endocrinology
- #real-world evidence
- #growth hormone therapy
- Study reports real-world outcomes of once-weekly somatrogon vs. daily somatropin in pediatric GHD over 6-12 months.
- 58 patients (58.6% male) divided into somatrogon-naïve (n=20), somatrogon-switch (n=18), and somatropin (n=20) groups.
- After 12 months, height SDS increased comparably across groups (0.6–0.7), with similar height velocities (9.1–10.0 cm/year).
- IGF-1 SDS rose highest in somatrogon-naïve group (+2.2 vs. +0.9 in switch, +1.3 in somatropin); 15.8% of somatrogon patients had IGF-1 SDS >+2, managed without serious AEs.
- Body composition (bioimpedance) showed non-significant improvement in somatrogon-naïve children; quality of life (PedsQL, CBCL, MSPSS) remained stable (p>0.05).
- Conclusion: Once-weekly somatrogon is as effective and safe as daily somatropin, with stable psychosocial outcomes in GHD children.